Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Braz. j. otorhinolaryngol. (Impr.) ; 82(5): 558-566, Sept.-Oct. 2016. tab
Article in English | LILACS | ID: biblio-828234

ABSTRACT

ABSTRACT INTRODUCTION: Oral squamous cell carcinoma (OSCC) is a serious public health problem, due to its high mortality rate and worldwide rising incidence. OSCC susceptibility is mediated by interactions between genetic and environmental factors. Studies suggest that genetic variants encoding enzymes involved in folate metabolism may modulate OSCC risk by altering DNA synthesis/repair and methylation process. OBJECTIVE: The goals of this study were to evaluate the association of three genotypic polymorphism (MTHFR C677T, MTHFR A1298C and CBS 844ins68) and oral cancer risk in southeastern Brazilians and evaluate the interactions between polymorphisms and clinical histopathological parameters. METHODS: This case-control study included 101 cases and 102 controls in the state of Espírito Santo, Brazil. MTHFR genotyping was done by PCR-RFLP (polymerase chain reaction - restriction fragment length polymorphism) and CBS genotyping by PCR (polymerase chain reaction) analysis. RESULTS: MTHFR C677T polymorphism was associated with lymph node involvement. Genotype CT + TT acted as a protective factor. MTHFR A1298C AC + CC genotype was associated with tumor differentiation, and possibly with a better prognosis. In risk analysis, no correlation was observed between genotypes and OSCC. CONCLUSION: We concluded that MTHFR C677T, MTHFR A1298C and CBS 844ins68 polymorphisms were not associated with OSCC risk in southeastern Brazilians; however, we suggest a prognosis effect associated with MTHFR C677T and A1298C polymorphisms in OSCC.


Resumo Introdução: O carcinoma espinocelular oral (CECO) trata-se de um importante problema de saúde pública, devido à elevada taxa de mortalidade e incidência crescente em todo o mundo. A susceptibilidade ao CECO é mediada por interações entre fatores genéticos e ambientais. Estudos sugerem que as variantes genéticas que codificam as enzimas envolvidas no metabolismo do folato podem modular o risco de CECO, alterando a síntese/reparação do DNA e o processo de metilação. Objetivo: Os objetivos deste estudo foram avaliar a associação de três polimorfismos genotípicos (MTHFR C677T, MTHFR A1298C e CBS 844ins68) e o risco de câncer oral em brasileiros da região Sudeste, e avaliar as interações entre polimorfismos e parâmetros clínico-histopatológicos. Método: Este estudo de caso-controle incluiu 101 casos e 102 controles no estado do Espírito Santo, Brasil. A genotipagem do polimorfismo MTHFR foi realizada por PCR-RFLP (Reação de Polimerase em Cadeia - Polimorfismo no Comprimento de Fragmento de Restrição) e a do CBS por análise da PCR (Reação de Polimerase em Cadeia). Resultados: O polimorfismo MTHFR C677T foi associado ao envolvimento de gânglios linfáticos. O genótipo CT + TT atuou como um fator protetor. O genótipo MTHFR A1298C AC + CC foi associado à diferenciação do tumor e, possivelmente, a um prognóstico melhor. Na análise de risco, a correlação entre os genótipos e o CECO não foi observada. Conclusão: Concluímos que os polimorfismos MTHFR C677T, MTHFR A1298C e CBS 844ins68 não estão associados ao risco de CECO nos brasileiros da região Sudeste; no entanto, sugerimos um efeito prognóstico associado aos polimorfismos MTHFR C677T e A1298C em CECO.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Mouth Neoplasms/enzymology , Carcinoma, Squamous Cell/enzymology , Genetic Predisposition to Disease/genetics , Cystathionine beta-Synthase/genetics , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Prognosis , Polymorphism, Restriction Fragment Length , Mouth Neoplasms/genetics , Carcinoma, Squamous Cell/genetics , Case-Control Studies , Polymerase Chain Reaction , Genotype , Neoplasm Staging
2.
Indian J Hum Genet ; 2011 May; 17(Suppl 1): 48-53
Article in English | IMSEAR | ID: sea-138984

ABSTRACT

BACKGROUND: Genetic variations represented as single nucleotide polymorphisms (SNPs) vary across the world population. This genetic polymorphism (such as SNPs) plays an important role in pharmacogenomics. SNPs that affects cellular metabolism, by altering the enzyme activity, have an important role in therapeutic outcome. Allele frequencies in number of clinically relevant SNPs within south Indian populations are not yet known. Hence, we genotyped randomly selected unrelated south Indian subjects from different locations of south India representing the heterogeneous ethnic background of the population. MATERIALS AND METHODS: Common variants of MTHFD1, TYMS, SHMT1, MTR, MTRR, CBS and SULT1A1 gene polymorphisms were screened from healthy unrelated south Indian volunteers. Genotypes were determined using RFLP analysis of polymerase chain reaction-amplified products and confirmed by DNA sequencing. Chi-square test was performed to test for deviation from the Hardy-Weinberg equilibrium for each locus. RESULTS: Gene allele frequency for several polymorphisms in our study differed significantly between the populations of other nations reported for several of the SNPs. These results demonstrate that the populations in different geographic regions may have widely varying genetic allele frequencies for clinically relevant SNPs. CONCLUSION: The present study reports, for the first time, the frequency distribution of MTHFD1, TYMS, SHMT1, MTR, MTRR, CBS and SULTIA1 gene polymorphisms in a south Indian population. Population-specific genetic polymorphism studies will help in practicing pharmacogenomic principles in the clinics.


Subject(s)
5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase/genetics , Arylsulfotransferase/genetics , Cystathionine beta-Synthase/genetics , Ferredoxin-NADP Reductase/genetics , Folic Acid/genetics , Genetic Variation/genetics , Glycine Hydroxymethyltransferase/genetics , Humans , Pharmaceutical Preparations/metabolism , Polymorphism, Genetic , Population Groups , Thymidylate Synthase/genetics
4.
Experimental & Molecular Medicine ; : 652-661, 2006.
Article in English | WPRIM | ID: wpr-106420

ABSTRACT

Homocystinuria is a metabolic disorder caused by a deficiency of cystathionine b-synthase (CBS). The major clinical symptoms of this disease are mental retardation, lens dislocation, vascular disease with life-threatening thromboembolisms, and skeletal deformities. The major treatments for CBS deficiency include pharmacologic doses of pyridoxine or dietary restriction of methionine. There is currently no effective long-term treatment to lower the elevated plasma levels of homocysteine. However, gene therapy could be an effective novel approach for the treatment of homocystinuria. A recombinant adeno- associated virus vector carrying human CBS cDNA (rAAV-hCBS) was constructed and administered to CBS-/- mice by intramuscular (IM) and intraperitoneal (IP) injections. Serum homocysteine concentrations significantly decreased in treated mice compared with age-matched controls two weeks after treatment. The treated CBS-/- mice had life spans 3-7 days longer compared with untreated CBS-/- mice. In CBS-/- mice treated with rAAV-hCBS via IP injection, the vector was detected in all organs examined including liver, spleen, and kidney, and CBS gene expression was observed by immunohistochemical staining in the liver. These results indicate the efficacy of gene delivery and demonstrate the possibility of gene therapy mediated by AAV gene transfer in this mouse model of homocystinuria.


Subject(s)
Mice , Humans , Animals , Survival Rate , Immunohistochemistry , Homocystinuria/enzymology , Homocysteine/blood , Gene Transfer Techniques , Genetic Therapy , Disease Models, Animal , Dependovirus/genetics , DNA, Recombinant/genetics , Cystathionine beta-Synthase/genetics , Cell Line
5.
NOVA publ. cient ; 3(3): 46-55, ene.-jun. 2005. ilus, tab, graf
Article in Spanish | LILACS | ID: lil-438605

ABSTRACT

Entre los errores innatos del metabolismo (EIM) que son defectos bioquímicos de origen genético se encuentra: la homocistinuria y la deficiencia de adenilosuccinato liasa (EC 4.3.2.2) (ADSL), la primera es frecuentemente producida por deficiencia de la cistationina ß sintasa (EC 4.2.1.22) (CßS) enzima que interviene en el catabolismo del aminoácido esencial metionina, la segunda es un defecto en el metabolismo de las purinas. Las manifestaciones clínicas de estas deficiencias son: para la CßS se comprometen sistemas del organismo como el ocular, músculo esquelético, vascular y sistema nervioso central; en el caso de ADSL, se presenta retardo mental, convulsiones, rasgos autistas, movimientos involuntarios, espasmo e hipoplasia cerebral. En este trabajo se escribe la secuencia utilizada en el diagnóstico de la homocistinuria y de la ADSL, a partir del uso de métodos químicos, bioquímicos y moleculares. Se estudiaron pacientes con sospecha clínica de estar afectados por un EIM; se emplearon las pruebas químicas como el nitroprusiato de sodio y de plata; separación de aminoácidos en plasma y orina por cromatografía de capa fina, técnicas bioquímicas para cuantificar la enzima CßS y técnicas moleculares para identificar la mutación que produce la homocistinuria. En el caso de la ADSL el diagnóstico se realizó por medio del test de Bratton Marshall con el cual se identifica la presencia de metabolitos de las purinas; luego por cromatografía de alta resolución (HPLC) para separar, identifica y cuantifica las succinilpurinas. Para el caso de la homocistinuria los resultados de nitroprusiato de sodio y de plata fueron positivos, la cuantificación enzimática mostró deficiencia de CßS y se llegó a identificar la presencia de una mutación. En el caso de la deficiencia de ADSL el test de Bratton Marshall fue positivo y la cuantificaron de metabolitos de las purinas se encontró aumentada.


Subject(s)
Adenylosuccinate Lyase/administration & dosage , Adenylosuccinate Lyase/analysis , Cystathionine beta-Synthase/administration & dosage , Cystathionine beta-Synthase/classification , Cystathionine beta-Synthase/genetics , Homocystinuria/classification , Homocystinuria/diagnosis
6.
Article in English | IMSEAR | ID: sea-95548

ABSTRACT

OBJECTIVE: The screening and therapeutic guidelines for the management of lipid abnormalities are reasonably well established. However, other risk factors like hyperhomocysteinemia (HCA) and single nucleotide polymorphisms involving the angiotensin converting enzyme (ACE) and angiotensinogen genes, various clotting factors etc., have yet to be established firmly as other causative factors of atherothrombotic disease. Our study was aimed at finding the relationship between HCA, folate, vitamins B12 levels, and mutations in the 5,10-methylenetetrahydrofolate reductase (MTHFR) and cystathionine beta-synthase (CBS) genes. METHODS: We studied 230 subjects, which included patients with angiographically documented coronary heart disease (CHD) (n=115) and controls (n=115) with no history of CHD. RESULTS: Elevated levels of plasma homocysteine, above 18 nmoles/ml, were detected in 19.13% and 18.26% of our patients and controls, respectively. Homocysteine was significantly correlated to Apo A1 (r=0.51, p < 0.05) and Apo B (r=0.49, p < 0.05). The heterozygous MTHFR mutation was found to be 54.5% (12/22) in our patients with HCA. Of these, 31.8% (7/22) were deficient for plasma folate. Heterozygosity for T833C mutation in the CBS gene was observed in 9.99% (2/22) of our patients with HCA. Both these patients were also deficient for plasma folate and vitamin B12. CONCLUSION: In our study, heterozygosity for the thermolabile MTHFR mutation was found to be associated with hyperhomocysteinemia (HCA). This genetic predisposition to HCA could be risk factor for CHD and can be correlated with vitamin supplementation. To the best of our knowledge this is the first report from India on plasma homocysteine levels and its genetic aspect in patients with CHD.


Subject(s)
Adult , Coronary Disease/blood , Cystathionine beta-Synthase/genetics , Female , Folic Acid/blood , Genotype , Homocysteine/blood , Humans , Hyperhomocysteinemia/blood , Male , Methylenetetrahydrofolate Reductase (NADPH2) , Middle Aged , Mutation , Oxidoreductases Acting on CH-NH Group Donors/genetics , Risk Factors , Vitamin B 12/blood
SELECTION OF CITATIONS
SEARCH DETAIL